|
 |
Environment > Pharmacokinetics
The following information is about Pharmacokinetics.
Pharmacokinetics Defined
The study of the way that drugs move through the body after they are swallowed or injected.
This definition is in context to Environment. See more contextual defintions for Pharmacokinetics.
OSI Pharmaceuticals Initiates Clinical Development Program For Anti-Diabetes Candidate, PSN821
Published September 5, 2008, 6:17 am, Medical News Today
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced that it has initiated a first-in-human clinical study for its G-protein coupled receptor GPR119 agonist, PSN821, which the Company is developing for the treatment of type 2 diabetes.
Azaya Therapeutics Licenses Promising Treatment For Head And Neck Cancers
Published September 5, 2008, 6:15 am, Medical News Today
Azaya Therapeutics, Inc., announced that it has signed a licensing agreement to further develop a breakthrough technology that uses liposomes to deliver radiation through direct injection into head and neck tumors, shrinking the tumor, delaying recurrence and avoiding the collateral tissue damage that often accompanies all other forms of radiation therapy.
Idenix Pharmaceuticals Announces Completion Of Proof-of-Concept Study For IDX899 In Treatment-Naive HIV-Infected ...
Published September 5, 2008, 5:15 am, Medical News Today
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, announced that it has completed the proof-of-concept study evaluating IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1.
Azaya licenses new technology for head and neck cancer treatment
Published September 5, 2008, 2:45 am, Pharmaceutical Business Review
US-based pharmaceutical company Azaya Therapeutics has signed a licensing agreement to further develop a technology that uses liposomes to deliver radiation through direct injection into head and neck tumors, shrinking the tumor, delaying recurrence and avoiding the collateral tissue damage that often accompanies all other forms of radiation therapy.
Stem Cell Sciences Announces The Creation Of The World's First Authentic Rat Embryonic Stem Cells From Its Exclusively ...
Published September 4, 2008, 3:10 am, Medical News Today
Stem Cell Sciences plc (AIM:STEM, ASX:STC), a company focused on the commercialisation of stem cells and stem cell technologies, is pleased to announce that two independent laboratories in the UK and USA have achieved germ-line transmission from embryonic stem (ES) cells in rats using technologies exclusively licensed to the company by Edinburgh University.
Diffusion Pharmaceuticals initiates phase I/II clinical trial in patients with peripheral arterial disease
Published September 3, 2008, 5:09 pm, News-Medical-Net
Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing new drugs for the treatment of unmet medical needs, announced today that it has begun to enroll patients in a Phase I/II clinical trial of its lead drug candidate trans sodium crocetinate (TSC).
Imovane
Published September 3, 2008, 12:48 pm, KFYR-TV Bismarck
The stay may be i was able to track that. Hello and was extremely low. In addition to the regulation, of which is usually the next day. Click here for the amount after taking the chemicals used for reference only. The pharmacokinetics of zopiclone on stage 2 sleep increased!
Azaya Therapeutics Licenses Promising Treatment for Head and Neck Cancers
Published September 3, 2008, 7:38 am, Centre Daily Times
Azaya Therapeutics, Inc., announced today that it has signed a licensing agreement to further develop a breakthrough technology that uses liposomes to deliver radiation through direct injection into head and neck tumors, shrinking the tumor, delaying recurrence and avoiding the collateral tissue damage that often accompanies all other forms of radiation therapy. The company plans to begin a ...
Azaya Therapeutics Licenses Promising Treatment for Head and Neck Cancers
Published September 3, 2008, 7:14 am, Business Wire via Yahoo! Finance
SAN ANTONIO----Azaya Therapeutics, Inc., announced today that it has signed a licensing agreement to further develop a breakthrough technology that uses liposomes to deliver radiation through direct injection into head and neck tumors, shrinking the tumor, delaying recurrence and avoiding the collateral tissue damage that often accompanies all other forms of radiation therapy.
Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in ...
Published September 2, 2008, 1:10 pm, PR Newswire via Yahoo! Finance
Alexza Pharmaceuticals, Inc. today announced positive results from its first Phase 3 clinical trial of AZ-004 in schizophrenic patients with acute agitation.
Are you looking for additional Environment > Pharmacokinetics news? Try our new "Pharmacokinetics News Focus" area.
Off-site Pharmacokinetics Links, User Submitted
The following links have been collected through user bookmark submission in the Pharmacokinetics category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.
Sun Aug 31
- Pharmacokineti c dosing - Aminoglycoside Dosing calculator
- MedCalc: PK - Vancomycin & Aminoglycoside s
Sun Aug 24
- Clinically relevant pharmacokineti c drug interactions with second-generat ion antidepressant s: An update. [Clin Ther. 2008 Jul;30(7):1206 -27.]: Second-generat ion antidepressant s differ in their potential for pharmacokineti c drug interactions. Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, and nefazodone is a substantial inhibitor of CYP3A4. Therefore, clinically relevant interactions may be expected when these antidepressant s are coadministered with substrates of the pertinent isozymes, particularly those with a narrow therapeutic index. Duloxetine and bupropion are moderate inhibitors of CYP2D6, and sertraline may cause significant inhibition of this isoform, but only at high doses. Citalopram, escitalopram, venlafaxine, mirtazapine, and reboxetine are weak or negligible inhibitors of CYP isozymes in vitro and are less likely than other second-generat ion antidepressant s to interact with co-administere d medications.
Sat Aug 23
Thu Aug 7
- Guidance Documents - Applications and Submissions - Drug Products
- The big Pharma lobby - Re: Vitamin C Injections Slow Tumor Growth In Mice - sci.med.nutrit ion | Google Groups: Decent collection of references on vitamin c pharmacokineti cs
Wed Jul 30
If you would like to find additional social bookmark based links on the topic of we recommend the Open Tag Directory > Pharmacokinetics. If you would like to find related tags we recommend Tag Patterns > Pharmacokinetics
Off-site Pharmacokinetics Research Links
If you still need additional information on Pharmacokinetics then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.
- A9 > Pharmacokinetics
- Alexa > Pharmacokinetics
- Anti-Aging Revolution > Pharmacokinetics
- DMOZ > Pharmacokinetics
- Feeds Filtered > Pharmacokinetics
- Google > Pharmacokinetics
- News Meme > Pharmacokinetics
- Nuah: News > Pharmacokinetics
- The Feed Directory > Pharmacokinetics
- OBP > Pharmacokinetics
- Open Tag Directory > Pharmacokinetics
- Podzy > Pharmacokinetics
- Yahoo > Pharmacokinetics
Environment Topics
Everything you need to know about Environment
Environment
If you know the Environment Term Name use the links below to quickly jump to your desired focus.
Bookmark Us
The On Topic Network
This website is part of The On Topic Network.
Thank You
Environment.On-Topic.net was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.
Best Viewed With
License
This work is licensed under Creative Commons.